INTS on Nasdaq

INTENSITY THERAPEUTICS, INC.

INTENSITY THERAPEUTICS, INC. is a late-stage clinical biotechnology company passionately.1 It is headquartered in Shelton, Connecticut.1 Its shares trade on Nasdaq under the symbol INTS.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with another stock.

  • TickerINTS on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersShelton, Connecticut1
  • Incorporated inDE2
  • Business address1 Enterprise Drive, Suite 430, Shelton, Ct 064842
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx SM discovery platform.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456-$12.0M in 2025+59% since 2022
-$20.0M-$15.0M-$10.0M-$5.0M02022: -$7.5M-$7.5M20222023: -$8.3M-$8.3M2023+10%2024: -$16.6M-$16.6M2024+99%2025: -$12.0M-$12.0M2025−28%
Net income456-$11.6M in 2025+53% since 2022
-$20.0M-$15.0M-$10.0M-$5.0M02022: -$7.6M-$7.6M20222023: -$10.5M-$10.5M2023+39%2024: -$16.3M-$16.3M2024+54%2025: -$11.6M-$11.6M2025−29%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Research and development$6.8M$10.5M
General and administrative$5.2M$6.1M
Total operating expenses$12.0M$16.6M
Loss from operations-$12.0M-$16.6M
Interest income$180.0K$314.0K
Other income, net$186.0K$3.0K
Net loss-$11.6M-$16.3M
Loss per share, basic (in dollars per share)-$8.56-$29.24
Loss per share, diluted (in dollars per share)-$8.56-$29.24
Weighted average number of shares of common stock, basic (in shares)1.4M shares556.3K shares
Weighted average number of shares of common stock, diluted (in shares)1.4M shares556.3K shares

Compare INTENSITY THERAPEUTICS, INC. with another company

Corporate structure

INTENSITY THERAPEUTICS, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of INTENSITY THERAPEUTICS, INC.

  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on INTENSITY THERAPEUTICS, INC., latest Aug 14, 2025 (3 filings since Feb 14, 2025)
  • SAPIENT CAPITAL LLC Filed SCHEDULE 13G/A on INTENSITY THERAPEUTICS, INC., latest Jul 9, 2025 (2 filings since Dec 30, 2024)
  • LFP Management, LLC Filed SC 13G on INTENSITY THERAPEUTICS, INC., latest Jun 7, 2024
  • Lewis H. Bender Filed SC 13G on INTENSITY THERAPEUTICS, INC., latest Feb 13, 2024
  • INTENSITY THERAPEUTICS, INC. Shelton, Connecticut

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What INTENSITY THERAPEUTICS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$96.0K6 Dec 31, 2025$122.0K6 Dec 31, 2024−21.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$11.9M6 Dec 31, 2025$2.6M6 Dec 31, 2024+360.3%

Properties, in its own words

We currently maintain all of our operations at 1 Enterprise Drive, Suite 430, Shelton, Connecticut pursuant to a 5.5- year lease entered into in July 2023 (the “Shelton Lease”). We consider our current office space adequate for our current operations.

Item 2 of the 10-K filed Mar 27, 2026.3

Leadership

Who has led INTENSITY THERAPEUTICS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lewis H. Bender2023–now

President

  1. Lewis H. Bender2023–now

Chief financial officer

  1. Joseph Talamo2023–now
2025
Board members and other officers (5)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorDaniel H. Donovan named Dec 5, 202415

Timeline

  1. Aug 11, 20268-K Results of operations16
  2. Jun 16, 20268-K Shareholder vote17
  3. May 7, 20268-K Results of operations18
  4. Mar 27, 20268-K Results of operations19
  5. Mar 23, 20268-K Other events20
  6. Mar 6, 20268-K Other events21
  7. Mar 5, 20268-K Results of operations22
  8. Feb 13, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events23
  9. Dec 5, 20258-K Listing notice or transfer24
  10. Dec 4, 20258-K Other events25
  11. Nov 6, 20258-K Results of operations26
  12. Oct 31, 20258-K Entered a material agreement; Other events27
  13. Jun 29, 2023New chief executive Lewis H. Bender becomes CEO9

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.50) a share, on Nov 6, 2025.28

When it reported results

  1. Aug 11, 2026Reported quarterly or annual results16
  2. May 7, 2026Reported quarterly or annual results18
  3. Mar 27, 2026Reported quarterly or annual results19
  4. Mar 5, 2026Reported quarterly or annual results22
  5. Nov 6, 2025Reported quarterly or annual results26
  6. Aug 7, 2025Reported quarterly or annual results29
  7. May 13, 2025Reported quarterly or annual results30
  8. Mar 13, 2025Reported quarterly or annual results31

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

239 filings to the SEC since October 2021: 3 annual reports, 11 quarterly reports, 45 major events, 41 insider forms, 7 large holders, 1 private raises, 131 other. The latest 20:

  1. Aug 11, 20268-K EDGAR
  2. Aug 11, 202610-Q EDGAR
  3. Jul 20, 20264 EDGAR
  4. Jul 20, 20264 EDGAR
  5. Jul 20, 20264 EDGAR
  6. Jul 20, 20264 EDGAR
  7. Jul 20, 20264 EDGAR
  8. Jul 20, 20264 EDGAR
  9. Jul 20, 20264 EDGAR
  10. Jul 8, 2026S-8 EDGAR
  11. Jul 1, 20264 EDGAR
  12. Jul 1, 20264 EDGAR
  13. Jun 16, 20268-K EDGAR
  14. May 7, 20268-K EDGAR
  15. May 7, 202610-Q EDGAR
  16. Apr 30, 2026ARS EDGAR
  17. Apr 30, 2026DEFA14A EDGAR
  18. Apr 30, 2026DEF 14A EDGAR
  19. Mar 30, 20264 EDGAR
  20. Mar 27, 20268-K EDGAR

The 239 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Lewis H. Bender67$549.1K$1.4M36
2025Joseph Talamo57$374.7K$723.7K36
2025John Wesolowski67$246.8K$378.5K36
2024President and Chief Executive Officer$544.1K$2.5M36
2024Chief Financial Officer$370.0K$1.7M36
2024Principal Accounting Officer and Controller$251.3K$569.1K36

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 21, 2024Raised $3.6 million in a private offering of securities Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Kingsbury Capital Investment Advisors LLC496,493$2.0M1.7%+458,439
Kmt Wealth Management, LLC496,493$2.0M1.7%New
Rothschild Wealth LLC26,723$109.6K0.0%+3,429
Vanguard Capital Management LLC26,569$108.9K0.0%+9,728
Sapient Capital LLC26,006$106.6K0.0%No change
Nano Cap New Millennium Growth Fund L P25,000$102.5K0.1%No change
Geode Capital Management, LLC22,787$93.4K0.0%−3,232
Mesirow Financial Investment Management, Inc.14,118$57.9K0.0%No change
Vanguard Fiduciary Trust Co9,121$37.4K0.0%No change
Tower Research Capital LLC (TRC)1,984$8.1K0.0%+1,917
NewEdge Advisors, LLC1,148$4.7K0.0%No change
Osaic Holdings, Inc.200$8200.0%No change
Barclays PLC42$1720.0%New
Morgan Stanley20$820.0%No change
Caitong International Asset Management Co., Ltd6$250.0%New
UBS Group AG1$40.0%−191

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How INTENSITY THERAPEUTICS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARINTENSITY THERAPEUTICS, INC.1
  • CIK0001567264
  • Employer ID (EIN)46-14880893
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1 Enterprise Drive, Suite 430, Shelton, CT 064841
  • Phone203-221-73811
  • Shares outstanding3,264,879 as of Aug 7, 20268
  • Public float$7.4M as of Jun 30, 20253
  • AuditorEisnerAmper LLP, New York, New York PCAOB ID 274; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJan 18, 20131
  • Filings244 in all: 8-K (45), CORRESP (38), 4 (33), S-1/A (17), UPLOAD (15), FWP (12), 10-Q (10), 424B5 (9)1
    All 32 form types

    3 (8), EFFECT (5), S-8 (5), SEC STAFF LETTER (5), DEF 14A (4), DEFA14A (4), 10-K (3), ARS (3), D (3), S-1 (3), SCHEDULE 13G/A (3), 424B4 (2), D/A (2), DRS (2), S-3 (2), SC 13G (2), SCHEDULE 13G (2), 10-Q/A (1), 424B3 (1), 8-A12B (1), 8-A12B/A (1), CERT (1), PRE 14A (1), S-1MEF (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Apr 30, 2026
    Latest 8-K (8-K) Aug 11, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareINTSThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 27, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks INTENSITY THERAPEUTICS, INC. names in Item 1A of its 10-K filed Mar 27, 2026: 61 risks under these headings, as written.3

  • Risks Related to Our Business, Financial, and Investment Conditions
  • The market price of our Common Stock may be highly volatile, and you could lose all or part of your investment.
  • We are a late-stage clinical biotechnology company with a limited operating history and have not generated any revenue to date from product sales.
  • We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.
  • The report by our auditors includes a paragraph that states that substantial doubt exists about the Company’s ability to continue as a going concern.
  • If we fail to establish and maintain an effective system of internal control, we may not be able to report our financial results accurately or to prevent fraud. Any inability to report and file our financial results accurately and timely could harm our reputation and adversely impact the future trading price of our securities.
  • We will need to raise substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate some or all of our product development programs or commercialization efforts.
  • We are largely dependent upon the success of our new intratumoral technology, which will require additional development before we may be able to seek regulatory approval and may never receive regulatory approval or be successfully commercialized.
  • We have limited experience conducting cancer clinical trials, and we are subject to risks and challenges that may prevent or delay the completion of our upcoming or on-going clinical trials.
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  • Our prospects for obtaining additional financing, as needed, are uncertain and our failure to obtain needed financing could affect our ability to pursue future growth.
  • Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
The other 50 risks
  • Changes to U.S. tariff and import/export regulations may have an adverse effect on our business, financial condition and results of operations.
  • Risks Related to FDA and Foreign Regulatory Approval
  • Clinical development involves a lengthy, complex and expensive process, with an uncertain outcome, and the results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials.
  • We will likely need separate regulatory approvals for every therapeutic agent or combination of compounds that we intend to develop and market using our technology.
  • Failure to obtain, or delay in obtaining, regulatory approvals would likely have a material adverse effect on our business, financial condition and results of operations.
  • We are not permitted to market products made using our technology in the United States unless and until we obtain regulatory approval from the FDA.
  • Delays in FDA approval could be costly to us and prevent us from commercializing our product candidates effectively.
  • We have received one fast track designation, and may continue to seek breakthrough therapy designations or other fast track designations from the FDA, for certain of our product candidates in certain indications, but receipt of either such designation may not actually lead to a faster development or regulatory review or approval process.
  • Even though the FDA granted INT230-6 orphan drug designation in June 2022, and even if we are granted orphan drug designations in the United States for any of our product candidates, there can be no guarantee that we will maintain orphan status for these product candidates or receive approval for any product candidate with an orphan drug designation.
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • We will rely on third parties to conduct certain of the preclinical research and any clinical trials for products using our technology, and if those third parties perform in an unsatisfactory manner, it may harm our business.
  • Even if products using our technology are approved by the FDA or any other regulatory agency, we will be subject to additional ongoing regulatory obligations and oversight in the U.S. and other countries where we obtain approval.
  • Even if we obtain regulatory approval for our product candidates using our technology in the United States, our ability to market a product would be limited to those uses that are approved for that product.
  • If we do not obtain required approvals in other countries in which we aim to market our product candidates, we will not be able to export or sell the products in those markets, which will limit our sales opportunities.
  • If no product candidates using our technology are approved by the FDA or other regulatory body, third-party payors in the United States or anywhere will not reimburse the use of our product candidates. Even if approval is obtained, our products may become subject to inadequate reimbursement, unfavorable pricing regulations or healthcare reform initiatives, which may harm results of operations.
  • Risks Related to Manufacturing, Commercialization, and Market Acceptance of Products made using our Technology.
  • We intend to rely on third parties to produce clinical and commercial supplies of our product candidates.
  • We purchase components for our product candidates from third parties, some of which may be sole-source suppliers.
  • We have not entered into long term manufacturing and supply agreements with any producers.
  • If we cannot successfully purchase or produce the drugs used in the manufacture of our product candidates, our ability to develop and commercialize products using our technology would be impaired.
  • Our current and future relationships with investigators, health care professionals, consultants, third-party payors, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
  • If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • We have limited experience in marketing and commercializing products and, as a result, we may not be successful in commercializing products made using our technology.
  • Even if we are successful in commercializing products using our technology in the United States, we may not be successful in other foreign countries.
  • Our plan to use collaborative arrangements with third parties to help finance and to market and sell products using our technology may not be successful.
  • We will be dependent on healthcare professionals’ efforts to learn about our product candidates.
  • We may need to establish clinical training and centers of excellence to educate and train physicians and healthcare payors, but the key opinion thought leadership required for initial market acceptance within the healthcare arena may take time to develop.
  • Healthcare legislative reform measures may have a negative impact on our business and results of operations.
  • If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
  • Rapid technological developments in treatment methods for cancer and competition with other forms of cancer treatments could affect our ability to achieve meaningful revenues or profit.
  • The loss of key personnel could adversely affect our business.
  • Our employees, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • Risks Related to Patents, Trade Secrets, and Proprietary Rights
  • Our success depends in part on our ability to obtain patents, maintain trade secret protection, operate without infringing on the proprietary rights of third parties, and commercialize our technology prior to the expiration of our patent protection.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.
  • Companies in the medical drug/device industry may use intellectual property infringement litigation to gain a competitive advantage.
  • If a third party violates our intellectual property rights, we may be unable to enforce our rights because of our limited resources.
  • Trade secret protection does not prevent independent discovery of the technology or proprietary information or use of the same.
  • Risks Related to Products Liability
  • We may be the subject of product liability claims or product recalls, and we may be unable to maintain insurance adequate to cover potential liabilities.
  • Risks Related to Our Securities
  • We are an “emerging growth company” as defined in the JOBS Act and a “smaller reporting company” as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our securities less attractive to investors and adversely affect the market price of our securities.
  • The price of our Common Stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our Common Stock.
  • Global, market and economic conditions may negatively impact our business, financial condition and share price.
  • Sales of our common stock under our at-the-market offering sales agreement may result in significant dilution to our existing stockholders.
  • Sales of a substantial number of shares of our Common Stock by our existing stockholders in the public market could cause our stock price to fall.
  • We may not satisfy the Nasdaq Capital Market’s requirements for continued listing of our common stock. If we cannot satisfy these requirements, the Nasdaq Capital Market could delist our common stock.
  • Our management will have broad discretion in using the cash and cash equivalents and may not use these proceeds effectively, which could affect our results of operations and cause our stock price to decline.
  • We do not anticipate paying dividends in the foreseeable future.
  • Provisions in our charter documents and Delaware law may deter takeover efforts that could be beneficial to stockholder value.
  • Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • Our board of directors could issue additional shares of Common Stock or a new class of preferred stock and dilute the equity positions of current stockholders without consent of the investors.
  • Our net operating loss carryforwards might not be able to be utilized in the future.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
    SEC EDGAROther events
  21. 21
    SEC EDGAROther events
  22. 22
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36